SCHEDULE 13D/A
SCHEDULE 13D/ASchedule 13D ownership disclosure
Mirum Pharmaceuticals Inc
Common Stock, par value $0.0001 per share · CUSIP: 604749101
Event date: 2025-11-01
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Frazier Life Sciences IX, L.P.Reported CIK 0001720320
Shares: 3,566,912.00 · Class: 7.1%
- FHMLS IX, L.P.Reported CIK 0001782789
Shares: 3,566,912.00 · Class: 7.1%
- FHMLS IX, L.L.C.Reported CIK 0001782791
Shares: 3,566,912.00 · Class: 7.1%
- Frazier Life Sciences X, L.P.Reported CIK 0001790879
Shares: 168,308.00 · Class: 0.3%
- FHMLS X, L.P.Reported CIK 0001790880
Shares: 168,308.00 · Class: 0.3%
- FHMLS X, L.L.C.Reported CIK 0001790811
Shares: 168,308.00 · Class: 0.3%
- Frazier Life Sciences Public Fund, L.P.Reported CIK 0001863769
Shares: 2,514,947.00 · Class: 5.0%
- FHMLSP, L.P.Reported CIK 0001879466
Shares: 2,514,947.00 · Class: 5.0%
- FHMLSP, L.L.C.Reported CIK 0001879465
Shares: 2,514,947.00 · Class: 5.0%
- Frazier Life Sciences XI, L.P.Reported CIK 0001911592
Shares: 544,954.00 · Class: 1.1%
- FHMLS XI, L.P.Reported CIK 0001911580
Shares: 544,954.00 · Class: 1.1%
- FHMLS XI, L.L.C.Reported CIK 0001911623
Shares: 544,954.00 · Class: 1.1%
- James N. TopperReported CIK 0001341382
Shares: 3,735,220.00 · Class: 7.4%
- Patrick J. HeronReported CIK 0001365617
Shares: 3,735,220.00 · Class: 7.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001231919-25-000420
- Form type
- SCHEDULE 13D/A
- Filer
- Frazier Life Sciences IX, L.P.
- CIK
- CIK 1720320
- Filed
- Nov 04, 2025
- Reporting period
- Nov 01, 2025
- Description
- Schedule 13D beneficial ownership